Introduction: Heart failure (HF) still remains as one of the most common causes of hospital admission with a high mortality rate. Aim: To investigate the possible prognostic role of brain natriuretic peptide (BNP), high-sensitivity (hs) cardiac troponin (cTn) I, cystatin C, and cancer antigen 125 (CA125) in the prediction of decompensation after an index hospitalization and to investigate their possible additive prognostic value. Patients and Methods: Two hundred twenty-two patients hospitalized with acute HF were monitored and followed for 18 months. Results: BNP at discharge has the highest sensitivity and specificity in the prediction of decompensation. For a cutoff value of 423.3 pg/ml, sensitivity was 64.3% and specificity was 64.5%, with a positive predictive value of 71.6% and an area under the curve (AUC) of 0.69 (P < 0.001). The hazard risk (HR) for decompensation when the discharge BNP was above the cutoff value was 2.18. Cystatin C, at a cutoff value of 1.46 mg/L, had a sensitivity of 57% and specificity of 57.8%, with a positive predictive value of 65.8% and an AUC of 0.59 (P = 0.028). CA125, in the prediction of decompensation in patients with acute heart failure (AHF) and at a cutoff value of 80.5 IU/L, had a sensitivity of 60.5% and specificity of 53.3%, with a positive predictive value of 64.5% and an AUC of 0.59 (P = 0.022). The time till onset of decompensation was significantly shorter in patients with four versus three elevated biomarkers (P = 0.047), with five versus three elevated biomarkers (P = 0.026), and in patients with four versus two elevated biomarkers (P = 0.026). The HR for decompensation in patients with five positive biomarkers was 3.7 (P = 0.001) and in patients with four positive biomarkers was 2.5 (P = 0.014), compared to patients who had fewer positive biomarkers. Conclusion: BNP, cystatin C, and CA125 are predictors of decompensation, and their combined usage leads to better prediction of new decompensation.

Analysis of mechanical properties of external unilateral fixation device „ Ultra X “, in the case of torque load, is presented in this paper. Fixation device is applied on lower leg in the case of unstable fracture. Computer aided design (CAD) model and finite element model (FEM) are developed according to the dimensions and material properties of real fixation device. In the next step principal stress and deformation analysis is performed in CATIA V5 software. During numerical analysis values of stresses at critical places are monitored and analyzed. In addi - tion, values of displacements are measured on important places on fixation device and bone fracture. Using values of displacements at the place of bone fracture, stiffness of the fracture is calculated. The same methodology is used to calculate stiffness of the fixation device. Using obtained results, several conclusions about the mechanical properties of the fixation device “Ultra X” are formulated at the end of the paper.

Introduction: Musculoskeletal disorders (MSDs) are common in men and women of all ages in all sociodemographic strata of society. Pain and functional limitations caused by MSDs severely limit independence and quality of life and interfere with an individual’s ability to participate in family and social life and work. The aim of this study is to investigate the effects of the Kinesio Tape (KT) technique on pain intensity in patients with MSDs of the upper and/or lower extremities before, during, and after therapeutic treatment. Methods: The study involved 123 patients of both sexes and all ages diagnosed with MSDs of the upper and/or lower extremities. Patients were randomly divided into two groups, a control group and an experimental group. The control group received the standard therapy protocol for MSDs, while the experimental group received the standard therapy protocol for MSDs plus the KT technique on the treated segment. The brief pain inventory was used to assess pain intensity. Both groups of participants were tested with the research instruments at baseline, during and after therapeutic treatment. Results: The ability to walk due to pain was significantly less impaired in the control group than in participants in the experimental group, in whom pain significantly impeded walking (p < 0.001). Normal walking was significantly more impaired in the experimental group than in the control group (p = 0.001). Pain significantly impaired relationships with others in the experimental group compared to the control group (p < 0.001). Conclusion: Subjects in the experimental group showed a significant decrease in pain in all areas after therapeutic treatment with KT compared to subjects in the control group.

Takotsubo syndrome (TTS) is an acute heart failure syndrome characterised by catecholamine-induced oxidative tissue damage. Punica granatum, a fruit-bearing tree, is known to have high polyphenolic content and has been proven to be a potent antioxidant. This study aimed to investigate the effects of pomegranate peel extract (PoPEx) pre-treatment on isoprenaline-induced takotsubo-like myocardial injury in rats. Male Wistar rats were randomised into four groups. Animals in the PoPEx(P) and PoPEx + isoprenaline group (P + I) were pre-treated for 7 days with 100 mg/kg/day of PoPEx. On the sixth and the seventh day, TTS-like syndrome was induced in rats from the isoprenaline(I) and P + I groups by administering 85 mg/kg/day of isoprenaline. PoPEx pre-treatment led to the elevation of superoxide dismutase and catalase (p < 0.05), reduced glutathione (p < 0.001) levels, decreased the thiobarbituric acid reactive substances (p < 0.001), H2O2, O2− (p < 0.05), and NO2− (p < 0.001), in the P + I group, when compared to the I group. In addition, a significant reduction in the levels of cardiac damage markers, as well as a reduction in the extent of cardiac damage, was found. In conclusion, PoPEx pre-treatment significantly attenuated the isoprenaline-induced myocardial damage, primarily via the preservation of endogenous antioxidant capacity in the rat model of takotsubo-like cardiomyopathy.

.

Abstract In this paper six heterobranch mollusc species are reported for the first time for Bosnia and Herzegovina: Berthellina edwardsi (Vayssiere, 1896), Felimida luteorosea (Rapp, 1827), Thuridilla hopei (Verany, 1853), Dendrodoris grandiflora (Rapp, 1827), Camachoaglaja africana (Pruvot-Fol, 1953) and Felimare villafranca (Risso, 1818). The study was conducted in October 2021 on Klek Peninsula and in Neum Bay (eastern Adriatic Sea, Bosnia and Herzegovina). This paper significantly extends the knowledge of the national marine heterobranch molluscs fauna, almost doubling the number of species known for the country, as only seven heterobranch species were reported for Bosnia and Herzegovina until now.

One of the key research directions to increase the capacity of new radio (NR) vehicle-to-everything (V2X) communication systems is extension of employed frequency bands from sub-6 GHz to millimeter wave (mmWave) range. To investigate different propagation effects between sub-6 GHz and mmWave bands in high-mobility scenarios, one needs to conduct channel measurements in both frequency bands. Using a suitable testbed setup to compare these two bands in a fair manner, we perform channel measurements at center frequencies of 2.55 GHz and 25.5 GHz, velocities of 50 km/h and 100 km/h, and at 126 different spatial positions. Furthermore, we conduct a comparative study of the multi-band propagation based on measurement results. We estimate the power delay profile (PDP) and the Doppler power spectral density (DSD) from a large set of measurements collected in a measurement campaign. Finally, we compare measured wireless channels at the two employed frequency bands in terms of root-mean-square (RMS) delay spread and RMS Doppler spread.

Abstract This paper studies the extent individuals are willing to undertake energy efficiency measures, with evidence coming from a developing country (Bosnia and Herzegovina). The goal of this paper is to analyze energy-savings behaviors, aiming to understand what is typically meant under the term energy efficiency, who is more likely to know the meaning, and the extent individuals are willing to undertake some energy efficiency measures. The sample size used in this paper is a random stratified sample of 1,415 individuals coming from various backgrounds. Our logistic regression models found no statistically significant predictor across all ten measures used in the study. However, past experience, age, and being married are relatively common across these ten energy-saving behaviors. These results might be beneficial in defining policies in order to promote energy-saving behaviors.

Despite patients with stage II melanoma being relatively high risk, contributing to 30% of melanoma-associated deaths, there remains a relatively low individual chance of melanoma recurrence. Therefore, strategies are required to better select those patients at highest risk of recurrence. We have developed assays using circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) or molecular recurrence of melanoma. Originally, the DETECTION trial was designed to perform ctDNA sampling in addition to clinical follow-up in patients with stage IIB/C melanoma. Those with ctDNA detected were randomized 1 : 1 in a double-blind fashion to continue routine follow-up with the investigators’ choice of treatment if they developed disease recurrence or were unblinded and treated with nivolumab. Since its opening, adjuvant therapy has been licensed, with trials showing approximately 6% absolute reduction in distant metastasis in stage IIB/C melanoma with 1 year of antiprogrammed cell death protein 1 therapy; however, grade 3 or 4 toxicity was observed in 16% of patients, with 25% experiencing lifelong endocrine disorders. Better enrichment of patients at high risk of recurrence, and avoiding treatment toxicity in those who do not require it, therefore remains highly relevant. As DETECTION had only started recruitment, there was opportunity to redesign it, which we present here. We have designed tumour-informed assays targeting BRAF (V600E/K/R), NRAS (G12D, Q61K/L/R) and the H-TERT promoter region (−124 and −146) mutations for ctDNA detection using droplet digital polymerase chain reaction. DETECTION has been redesigned as a phase III trial with the primary objectives of elucidating (i) whether MRD/molecular relapse following curative intent surgery can be identified earlier than clinical relapse and (ii) whether early treatment of molecular recurrence based on ctDNA detection is noninferior to adjuvant therapy in preventing distant metastasis. Patients (n = 1000) with stage IIB/C/III/IV resected BRAF/NRAS/TERT promoter mutant cutaneous melanoma, ECOG 0/1 and adequate organ function, with complete resection performed within 12 weeks and radiological/clinical disease-free status confirmed and no prior immune/targeted therapy will be included. Patients will be randomized 1 : 1 to either 1 year of adjuvant therapy (arm A) or longitudinal ctDNA monitoring (arm B) and treatment only if a local recurrence (surgery followed by 1 year of adjuvant therapy with ongoing ctDNA monitoring) or ctDNA detection (2 years of the investigators’ choice of therapy). The primary endpoint is distant metastasis-free survival. CtDNA is a useful tool to monitor for MRD/molecular relapse. The DETECTION trial will assess whether it can be used to safely monitor patients and systemically treat only those at highest risk of melanoma progression.